XBiotech (NASDAQ:XBIT – Get Free Report) and Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Institutional & Insider Ownership
55.7% of XBiotech shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares XBiotech and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XBiotech | N/A | -26.10% | -25.06% |
| Mosaic ImmunoEngineering | N/A | N/A | -1,908.81% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XBiotech | 1 | 0 | 0 | 0 | 1.00 |
| Mosaic ImmunoEngineering | 0 | 0 | 0 | 0 | 0.00 |
Volatility & Risk
XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500.
Valuation and Earnings
This table compares XBiotech and Mosaic ImmunoEngineering”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XBiotech | N/A | N/A | -$45.54 million | ($1.32) | -1.78 |
| Mosaic ImmunoEngineering | N/A | N/A | -$690,000.00 | ($0.09) | -7.49 |
Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.
Summary
XBiotech beats Mosaic ImmunoEngineering on 5 of the 9 factors compared between the two stocks.
About XBiotech
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.
